SG11201708679YA - Reagents for treatment of hepatitis b virus (hbv) infection and use thereof - Google Patents
Reagents for treatment of hepatitis b virus (hbv) infection and use thereofInfo
- Publication number
- SG11201708679YA SG11201708679YA SG11201708679YA SG11201708679YA SG11201708679YA SG 11201708679Y A SG11201708679Y A SG 11201708679YA SG 11201708679Y A SG11201708679Y A SG 11201708679YA SG 11201708679Y A SG11201708679Y A SG 11201708679YA SG 11201708679Y A SG11201708679Y A SG 11201708679YA
- Authority
- SG
- Singapore
- Prior art keywords
- hbv
- hepatitis
- virus
- reagents
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015901617A AU2015901617A0 (en) | 2015-05-06 | Reagents for treatment of hepatitis B virus (HBV) infection and use thereof | |
US201662319971P | 2016-04-08 | 2016-04-08 | |
PCT/AU2016/050340 WO2016176745A1 (fr) | 2015-05-06 | 2016-05-06 | Réactifs pour le traitement de l'infection par le virus de l'hépatite b (vhb) et utilisation de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201708679YA true SG11201708679YA (en) | 2017-11-29 |
Family
ID=57217350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201708679YA SG11201708679YA (en) | 2015-05-06 | 2016-05-06 | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
Country Status (11)
Country | Link |
---|---|
US (2) | US10898505B2 (fr) |
EP (1) | EP3292202A4 (fr) |
JP (1) | JP7191690B2 (fr) |
KR (1) | KR20170141257A (fr) |
CN (1) | CN107683336A (fr) |
AU (2) | AU2016257150B2 (fr) |
CA (1) | CA2984512A1 (fr) |
HK (1) | HK1251010A1 (fr) |
IL (1) | IL255366B (fr) |
SG (1) | SG11201708679YA (fr) |
WO (1) | WO2016176745A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3452595A4 (fr) * | 2016-05-05 | 2020-02-19 | Benitec Biopharma Limited | Réactifs pour le traitement d'infection par le virus de l'hépatite b (vhb) et utilisation de ceux-ci |
JP2019533472A (ja) * | 2016-11-11 | 2019-11-21 | ヤンセン バイオファーマ インク. | Hbv cccdnaのオリゴヌクレオチド標的化戦略 |
US20210395751A1 (en) * | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
CN110592289A (zh) * | 2019-10-31 | 2019-12-20 | 苏州健雄职业技术学院 | 一种高灵敏度hbv dna数字pcr定量检测试剂盒及其应用 |
CN112280896A (zh) * | 2020-09-30 | 2021-01-29 | 浙江大学 | 一种基于微滴式数字pcr技术的乙型肝炎病毒t216c突变检测方法 |
WO2023122805A1 (fr) | 2021-12-20 | 2023-06-29 | Vestaron Corporation | Procédé de pression de sélection par sorbitol |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
WO1992002534A2 (fr) | 1990-08-03 | 1992-02-20 | Sterling Drug, Inc. | Composes et procedes d'inhibition de l'expression de genes |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
JPH08500481A (ja) | 1992-05-11 | 1996-01-23 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | ウイルスの複製を阻害するための方法および薬剤 |
US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
WO1994022891A1 (fr) | 1993-03-31 | 1994-10-13 | Sterling Winthrop Inc. | Oligonucleotides a liaisons d'amides remplacant les liaisons de phosphodiesters |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
US6054576A (en) | 1997-10-02 | 2000-04-25 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA |
ES2356342T3 (es) | 1998-01-05 | 2011-04-07 | The University Of Washington | Mejora de transporte utilizando agentes de alteración de membrana. |
US7273933B1 (en) | 1998-02-26 | 2007-09-25 | Isis Pharmaceuticals, Inc. | Methods for synthesis of oligonucleotides |
JP2003525017A (ja) | 1998-04-20 | 2003-08-26 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | 遺伝子発現を調節しうる新規な化学組成を有する核酸分子 |
US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
US6465628B1 (en) | 1999-02-04 | 2002-10-15 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
US7321029B2 (en) | 2000-01-21 | 2008-01-22 | Geron Corporation | 2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use |
JP2004522695A (ja) | 2000-09-01 | 2004-07-29 | サーナ・セラピューティクス・インコーポレイテッド | ヌクレオシド,ヌクレオシド誘導体および非ヌクレオシド誘導体を合成する方法 |
US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
WO2002087541A1 (fr) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Formulations a base de lipides pour transfert genique |
US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
US6989442B2 (en) | 2002-07-12 | 2006-01-24 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
JP2006515162A (ja) | 2002-08-29 | 2006-05-25 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 環状核酸ベクター、ならびに同ベクターの作製法および使用法 |
US7816337B2 (en) | 2003-02-18 | 2010-10-19 | Roche Madison Inc. | Reversible attachment of a membrane active polymer to a polynucleotide |
CN1836042A (zh) * | 2003-06-12 | 2006-09-20 | 原子核物理公司 | 用于基因沉默的hbv和hcv保守序列 |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
CN1322898C (zh) | 2003-06-17 | 2007-06-27 | 杭州新瑞佳生物医药技术开发有限公司 | 攻击人类乙型肝炎病毒的小干扰RNA分子(SiRNA)及其应用 |
EP2316942B1 (fr) * | 2004-12-22 | 2021-04-21 | Alnylam Pharmaceuticals, Inc. | Sequences vhb et vhc conservees utilisees pour un silençage genique |
AU2006336384B2 (en) | 2005-02-14 | 2010-12-16 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
US8008468B2 (en) | 2005-02-16 | 2011-08-30 | Benitec, Inc. | RNAi expression constructs with liver-specific enhancer/promoter |
US8129510B2 (en) | 2006-03-30 | 2012-03-06 | The Board Of Trustees Of The Leland Stanford Junior University | Minigene expression cassette |
CN102614528B (zh) | 2006-08-18 | 2014-02-26 | 箭头研究公司 | 用于体内递送多核苷酸的多缀合物 |
CN101322847A (zh) | 2008-06-23 | 2008-12-17 | 淮安市第四人民医院 | 基于siRNA池干扰的复合载体介导的抗乙肝病毒基因药物 |
EP2326331A4 (fr) | 2008-08-18 | 2013-05-15 | Merck Sharp & Dohme | Nouvelles nanoparticules lipidiques et nouveaux composants pour l'administration d'acides nucléiques |
ES2475065T3 (es) | 2008-10-09 | 2014-07-10 | Tekmira Pharmaceuticals Corporation | Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos |
WO2010080724A1 (fr) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Nanoparticules lipidiques inédites et composants inédits utilisables pour l'administration d'acides nucléiques |
CN102421900B (zh) | 2009-03-12 | 2015-07-22 | 阿尔尼拉姆医药品有限公司 | 用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法 |
US9512164B2 (en) | 2009-07-07 | 2016-12-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
US9181295B2 (en) | 2009-08-20 | 2015-11-10 | Sirna Therapeutics, Inc. | Cationic lipids with various head groups for oligonucleotide delivery |
EA201290152A1 (ru) * | 2009-10-16 | 2012-12-28 | Глаксо Груп Лимитед | Антисмысловые ингибиторы вируса гепатита в (hbv) |
JP2013537423A (ja) * | 2010-08-17 | 2013-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたB型肝炎ウイルス(HBV)遺伝子発現のRNA干渉媒介性阻害 |
WO2012109798A1 (fr) * | 2011-02-18 | 2012-08-23 | Benitec Biopharma Limited | Traitement du vhb |
US9080174B2 (en) * | 2010-10-28 | 2015-07-14 | Benitec Biopharma Limited | HBV treatment |
EP3418386B1 (fr) * | 2011-06-30 | 2021-04-07 | Arrowhead Pharmaceuticals, Inc. | Compositions et méthodes permettant d'inhiber l'expression d'un gène du virus de l'hépatite b |
WO2013159109A1 (fr) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation de l'expression du virus de l'hépatite b (hbv) |
CN103014045B (zh) | 2012-12-30 | 2014-09-17 | 中国人民解放军第三军医大学 | 表达特异性HBV shRNA的重组HBV载体及其构建方法和应用 |
-
2016
- 2016-05-06 CA CA2984512A patent/CA2984512A1/fr active Pending
- 2016-05-06 JP JP2018509947A patent/JP7191690B2/ja active Active
- 2016-05-06 SG SG11201708679YA patent/SG11201708679YA/en unknown
- 2016-05-06 CN CN201680036346.4A patent/CN107683336A/zh active Pending
- 2016-05-06 KR KR1020177035149A patent/KR20170141257A/ko unknown
- 2016-05-06 AU AU2016257150A patent/AU2016257150B2/en not_active Ceased
- 2016-05-06 EP EP16788971.6A patent/EP3292202A4/fr not_active Withdrawn
- 2016-05-06 US US15/572,143 patent/US10898505B2/en active Active
- 2016-05-06 WO PCT/AU2016/050340 patent/WO2016176745A1/fr active Application Filing
-
2017
- 2017-10-31 IL IL255366A patent/IL255366B/en unknown
-
2018
- 2018-08-13 HK HK18110340.6A patent/HK1251010A1/zh unknown
-
2020
- 2020-12-16 US US17/124,066 patent/US20210177885A1/en not_active Abandoned
-
2022
- 2022-05-30 AU AU2022203678A patent/AU2022203678A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL255366A0 (en) | 2017-12-31 |
AU2022203678A1 (en) | 2022-06-16 |
JP7191690B2 (ja) | 2022-12-19 |
IL255366B (en) | 2021-10-31 |
US20190022124A1 (en) | 2019-01-24 |
HK1251010A1 (zh) | 2019-01-18 |
KR20170141257A (ko) | 2017-12-22 |
US20210177885A1 (en) | 2021-06-17 |
EP3292202A1 (fr) | 2018-03-14 |
CN107683336A (zh) | 2018-02-09 |
US10898505B2 (en) | 2021-01-26 |
EP3292202A4 (fr) | 2019-04-10 |
WO2016176745A1 (fr) | 2016-11-10 |
AU2016257150B2 (en) | 2022-03-31 |
AU2016257150A1 (en) | 2017-11-09 |
JP2018515136A (ja) | 2018-06-14 |
CA2984512A1 (fr) | 2016-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL257384A (en) | Preparations containing rnai and their use for the treatment of infection with the hepatitis b virus | |
HK1248681A1 (zh) | 作為hbsag(hbv表面抗原)和hbv dna生成的抑制劑用於治療乙型肝炎病毒感染的四氫吡啶並嘧啶和四氫吡啶並吡啶類化合物 | |
HRP20190352T1 (hr) | Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b | |
HK1223931A1 (zh) | 用於治療和預防乙型肝炎病毒感染的新型二氫喹嗪酮類化合物 | |
HK1220935A1 (zh) | 治療乙型肝炎病毒感染的方法和藥物組合物 | |
HK1251010A1 (zh) | 用於治療乙型肝炎病毒(hbv)感染的試劑及用途 | |
HK1231402A1 (zh) | 治療 型肝炎和 型肝炎病毒感染的方法 | |
HUE054191T2 (hu) | A hepatitis delta vírusfertõzés kezelése | |
HUE044606T2 (hu) | A hepatitis delta vírusfertõzés kezelése | |
EP3226973A4 (fr) | Traitement d'une infection au virus de l'hépatite delta | |
IL271491B1 (en) | Treatment of carcinoma of the liver characterized by hepatitis b virus infection | |
EP3452595A4 (fr) | Réactifs pour le traitement d'infection par le virus de l'hépatite b (vhb) et utilisation de ceux-ci | |
IL286484B (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
HK1254547A1 (zh) | 抗病毒劑和治療病毒感染的方法 | |
AU2015901617A0 (en) | Reagents for treatment of hepatitis B virus (HBV) infection and use thereof | |
ZA201604784B (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |